Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 2,001–2,100 of 2,162
Ryder, S. W., & Weiner, E. S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50006-8
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
Myers, J. W., Peoples, G. E., & Clifton, G. T. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_6 · Cited by 1
Overview Of Antibody- Based Therapeutics Present And Future Promise
Grewal, I. S. (2009) · CRC Press eBooks · doi:10.1201/9781420063219.sec1 · Cited by 1
MacKenzie, C. R., & Paget, S. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00026-9
Kripp, M. (2013) · Humanmedizin kompakt · doi:10.1007/s40355-013-0014-5
Biotechnology Products and Their Development
Shapiro, D. A., & Fox, A. W. (2010) · doi:10.1002/9781444325263.ch24
van der Laan, J. W., Benson, C., Janssens, W., et al. (2019) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479019843514
Ethical Considerations in Cancer Immunotherapy
Markman, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_32
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0011
Choy, E. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00057-9
Special Concerns for Preclinical Evaluation of Biotechnology Products
(2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse143
General Toxicity Testing and Immunotoxicity Testing for Biopharmaceuticals
Bussiere, J. L. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse175
Midkine and Multiple Sclerosis
Takeuchi, H. (2012) · Springer eBooks · doi:10.1007/978-94-007-4234-5_12
Tuosto, L. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101843-1
Nathans, C. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100057
(2012) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2012.12.0144
Ueda, T. (2017) · Springer eBooks · doi:10.1007/978-981-10-3332-2_1
Petersen, H. J. (2019) · Oral Surgery · doi:10.1111/ors.12402
Jäger, S., & Schwab, M. G. (2021) · Springer eBooks · doi:10.1007/978-3-030-57499-4_43
He, X. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87403
Helm, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-35099-3_46
Clinical Evaluation of New Drugs: From the regulatior’s view point
山崎, 文., 哲夫, 中., & 猿田, 克. (2016) · JAPANES JOURNAL OF MEDICAL INSTRUMENTATION · doi:10.4286/jjmi.86.494
Yang, X., Toyofuku, W. M., & Scott, M. D. (2019) · Research Square · doi:10.21203/rs.2.18715/v1
Fischer, K. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-35099-3_42
Fontenot, A. P., & Simonian, P. L. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00014-6
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0004 · Cited by 1
Nanomaterials and immune system
Mohamed, N. K., Elsabahy, M., Wooley, K. L., & Eissa, N. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90604-3.00005-x
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.002.0004
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.002.0005
Non-clinical safety evaluations of next-generation therapeutic antibodies
Nihira, K. (2022) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22049
Article Review: The Phenomenon of Cytokine Storm
Aldoori, Z. A. A., & Hameed, N. I. A. (2022) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.1.4.21
SPECIAL CONCERNS FOR THE PRECLINICAL EVALUATION OF BIOTECHNOLOGY PRODUCTS
Gad, S. C., & Sullivan, D. W. (2022) · doi:10.1002/9781119755883.ch21
Cutaneous Adverse Reactions to Biologic Agents
Choo, K. J. L., & Yeo, Y. W. (2022) · Updates in clinical dermatology · doi:10.1007/978-3-031-09388-3_24
From Bench to Bedside: The First Studies of a New Molecule in Man
Darwin, K. L. R., Thomsen, L., & Boyce, M. J. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781782621423-00379
Innovative immune checkpoint inhibitors (ICIs) for cancer treatment: an overview
Ahmed, M. M. (2023) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2023.14.00531
Pathology in Nonclinical Drug Safety Assessment
Guffroy, M., & Li, X. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00033-6
Leach, M. W., & Hammerman, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00024-5
Feng, Y., Tichauer, K. M., & Samkoe, K. S. (2023) · doi:10.1117/12.2650968
Research and discovery: Essential partners but just a start
Miller, S. M., Moos, W. H., Munk, B. H., Munk, S. A., Hart, C. P., & Spellmeyer, D. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824304-6.00011-0
Sharma, R. K., Elpek, K. G., Yolcu, E. S., Schabowsky, R.-H., Zhao, H., Bandura‐Morgan, L., & Shirwan, H. (2023) · doi:10.1158/0008-5472.c.6498585.v1
Sharma, R. K., Elpek, K. G., Yolcu, E. S., Schabowsky, R.-H., Zhao, H., Bandura‐Morgan, L., & Shirwan, H. (2023) · doi:10.1158/0008-5472.c.6498585
Murgaski, A., Kiss, M., Damme, H. V., Kancheva, D., Vanmeerbeek, I., Keirsse, J., Hadadi, É., Brughmans, J., Arnouk, S. M., Hamouda, A. E. I., et al. (2023) · doi:10.1158/0008-5472.c.6514056.v1
Murgaski, A., Kiss, M., Damme, H. V., Kancheva, D., Vanmeerbeek, I., Keirsse, J., Hadadi, É., Brughmans, J., Arnouk, S. M., Hamouda, A. E. I., et al. (2023) · doi:10.1158/0008-5472.c.6514056
London, A. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.002.0004
London, A. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.002.0006
London, A. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.002.0003
London, A. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.002.0008
Singh, A., Verma, A. K., Pandey, A. K., & Bajpai, J. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815123197123010008
Gad, S. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00875-7
Cytokine storm: When the immune system goes into overdrive
Kale, P. P., Mani, A., Gurha, S., Abhishek, H. N., Kant, K., & Mustilwar, R. G. (2023) · Journal of Cellular Biotechnology · doi:10.3233/jcb-230091
“Baricitinib has been used in combination with remdesivir for the treatment of COVID-19 [20, 21].”
Noninfectious Disease Vaccines
Speiser, D. E., El-Turabi, A., & Bachmann, M. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00042-6
Aktivierung von Immunzellrezeptoren statt Checkpointblockade
Bald, T., & Glodde, N. (2023) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-023-0035-6
MacLeod, E., Rajagopal, D., & Vessillier, S. (2023) · Journal of Visualized Experiments · doi:10.3791/65087 · Cited by 1
The role of costimulation blockade in transplantology: from experiment to clinic
Grinko, E. K., Дмитриевна, Д. А., Varlachev, A. V., & Mitin, A. N. (2023) · Immunologiya · doi:10.33029/0206-4952-2023-44-5-626-639 · Cited by 2
The Development, Indications, and the Safety of Monoclonal Antibodies
Güney, H. Z. (2023) · Lokman Hekim Health Sciences · doi:10.14744/lhhs.2023.12008
Daratumumab for the treatment of multiple myeloma
Iversen, K. F., & Plesner, T. (2023) · Srpski medicinski casopis Lekarske komore · doi:10.5937/smclk4-47645
“Situaciju je dodatno zakom-plikovala nedavna katastrofa koja se dogodila prilikom kliničkog ispitivanja antitela CD38 koja je vlastima skrenula pažnju na potencijalnu opasnost koju može da izazove korišćenje monoklonskih antitela u vidu te-rapije [11].”
BackgroundStrategies to induce tolerance
McCallion, O., Hester, J., & Issa, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23571-9.00046-3
Non-human primates in preclinical development of monoclonal antibodies
Макарова, М. Н., & Makarov, V. G. (2023) · Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science) · doi:10.57034/2618723x-2023-02-01
Preclinical Development of Monoclonal Antibodies
Meyer-Tamaki, K. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00005-0
Principles of Systemic Therapy
Pink, A., Woolf, R., & Smith, C. H. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook019
Wu, Y., Ye, X., Zhu, Y., Liu, S., Song, J., Zhang, Y., Yuan, Q., Liu, F., Kong, D., & Zhao, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.21.586203
“For instance, in the 2006 TGN1412 phase I clinical trial involving CD28 monoclonal antibodies, six healthy male volunteers rapidly developed severe systemic inflammatory responses after receiving a single dose of the antibody, resulting in critical conditions 17 .”
Immunogenicity and Immune-Related Adverse Drug Reactions
Mihalcik, L., Bussiere, J. L., Allamneni, K. P., Jawa, V., Lepherd, M., Mytych, D. T., Sirivelu, M. P., & Everds, N. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00066-8
Animal Models of Transplantation
Short, S., Wood, K. J., Hester, J., & Issa, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00016-8
Clinical Development of Immune Checkpoint Inhibitor for Solid Tumors Other than Lung Cancer
Kitano, S., Miyamoto, I., Kurokawa, K., Miyawaki, E., & Mizugaki, H. (2024) · Haigan · doi:10.2482/haigan.64.158
3. Early Phase Exploratory Clinical Trial: Implementation of First In Human Trials
Hasunuma, T. (2024) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.55.3_156
Kamperschroer, C., Collinge, M., Heyen, J. R., Ji, C., O’Donnell, L. M., & Zhu, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00104-2
Development and Manufacture of a Multi-bench Cultivator for Bioreactors
Böhme, A., & Foitzik, A. H. (2024) · Mechanisms and machine science · doi:10.1007/978-3-031-63755-1_19
Cytokines: Role in Homeostasis and Disease States
Engström, A., Davies, J., & Kim, Y.-M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00042-5
Alajlan, A. A. M., Alanazi, . A. A., Fahad, A. I. A. A., Almorshed, A. S. A., Alrbian, A. A. M., Alsawaji, M. A. M., Al-Mutairi, N. H. B., & Otaibi, S. G. A. (2018) · International Journal of Health Sciences · doi:10.53730/ijhs.v2ns1.15289
“A CTLA-4-Ig fusion protein called abatacept, which inhibits T-cell activity and has demonstrated disease-modifying potential in murine models of lupus nephritis, has attracted a lot of attention [94-96].”
BackgroundNew strategies for solid tumor immunotherapy based on NK cells
Vorobyova, I. G., & Абакушина, Е. В. (2024) · Medical Immunology (Russia) · doi:10.15789/1563-0625-nsf-2938
Early de-risking strategy for biotherapeutics
Narayanan, P. K., Dahlman, A., & Peng, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00002-x · Cited by 1
Regulatory guidelines and their application in the nonclinical evaluation of biological medicines
Fuller, C. L., Dempster, M., & Todd, M. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00006-7
Considerations for nonclinical studies conducted to support the development of cellular therapies
Bolt, M. W., & Narayanan, P. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00011-0
10.1016/b978-1-4557-5414-4.00023-1
(2000) · Time to knit · doi:10.1016/b978-1-4557-5414-4.00023-1
10.1016/b978-2-294-08855-1.50015-2
(2000) · Time to knit · doi:10.1016/b978-2-294-08855-1.50015-2
Papenfuss, T. L., Schaudien, D., Amuzie, C. J., & Mohanan, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-821045-1.00006-7 · Cited by 1
Humanizing a CD28 signaling domain affects CD8 activation, exhaustion and stem-like precursorsPreprint
Brady, A. E., Revu, S. K., Wu, D., Fisk, H., Kone, K., Lydecker, A., Purser, E. J., Smith, N. L., Hilt, Z. T., Woodyear, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.10.642460
Immunophenotyping in Drug Development
Kimzey, A. L., Piche, M.-S., Wood, M., Weir, A. B., & Lansita, J. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00119-4
A trial‐blazer in clinical research
Johnston, A., Medhavy, A., Elliott, S. L., & Stanisic, D. I. (2025) · Immunology and Cell Biology · doi:10.1111/imcb.70034
Yoshitomi, R., & Sugiura, S. (2025) · Research Square · doi:10.21203/rs.3.rs-6713236/v1
Upadhyay, S., Talagayev, V., Cho, S., Wolber, G., & Gabr, M. T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.16.665260
“The most well-known is TGN1412, a superagonist antibody intended to expand regulatory T cells; however, it caused a life-threatening cytokine storm in a Phase I clinical trial, underscoring the risks associated with broad CD28 activation (Suntharalingam et al., 2006).”
Anti-angiogenesis enhances the tumor immunotherapeutical effect of recombinant CD80 fusion protein
Wang, S., Huang, L., Zhang, X., Fan, J., Zou, J., Hong, W., Tuerdi, A., Zhu, Y. Z., Hu, P., & Li, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146350
A New Era of Therapeutics: Innovation in the Treatment of Rheumatoid Arthritis
Romi, Sharma, D., Sharma, A., & Gupta, P. (2025) · Recent Advances in Anti-Infective Drug Discovery · doi:10.2174/0127724344382299250818070846 · Cited by 1
The Essential Role of Medical Monitors in Clinical Trials
Klein, G. L., Barabash, E., Morgan, R. E., et al. (2025) · Cureus · doi:10.7759/cureus.92388
“A well-known failure in protocol oversight occurred during the TGN1412 trial conducted in 2006 [11-13].”
Immunotoxicology of Biopharmaceutics
Haggerty, H. G., Price, K., & Shenton, J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.50043-6
The future of Italian phase I trials regulation: lessons from a nationwide survey
Cagnazzo, C., Penolazzi, L., Stabile, S., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1709108
A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritis
Lawson, C., Harry, R. A., Griffiths, B., Hale, G., Waldmann, H., & Isaacs, J. D. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf034
“The most infamous example of mAb-induced T-cell activation occurred with TGN-1412, with sequelae that included renal failure, lung injury and disseminated intra-vascular coagulation [21].”
Immunogenicity of a CXCL8-based biopharmaceutical drug candidate in comparison to its wildtype form
Talker, E., Gerlza, T., Stas, P., Trojacher, C., Adage, T., & Kungl, A. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679409
Antibody-Redirected T-Cell Immunotherapy for Brain Tumors
Choi, B. D. (2014) · DukeSpace (Duke University)
Exploitation of costimulatory SA-4-1BBL in the development of therapeutic cancer vaccines.
Srivastava, A. (2011) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/1367
Mécanismes cellulaires et moléculaires de l’immunodépression post-infectieuse
Grimaldi, D. (2013) · theses.fr (ABES) · doi:10.70675/5a898009z25d3z487fza92cz9dfb9e05d314
Development of CD19 binding reagents for targeted nanoparticles
Rogers, J. H. (2013) · UNM’s Digital Repository (University of New Mexico)
Webb, A. E. (2015) · Dublin City University Open Access Institutional Repository (Dublin City University)
Chen, M., Liu, X., Peng, N., Zhang, T., Mou, J., He, H., Wang, Y., Xu, Y., Xing, H., Tang, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26606278
Yarmush, M. L. (2025) · Innovation and Emerging Technologies · doi:10.1142/s2737599425200014
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.